Intracel OncoVAX Phase III Will Follow Patients For Three Years
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm says single pivotal trial of the autologous cancer vaccine can support a BLA for adjuvant treatment of Stage II colon cancer.
You may also be interested in...
Antigenics Improves Oncophage Vaccine Manufacturing Output Ahead Of Registration Trial
Non-registration Phase III trial shows extension in survival for Oncophage-treated arm in category M1a stage IV melanoma.
Dendreon Provenge Plant Completion Is Last Hurdle Before BLA Filing
Decision to move ahead follows talks with FDA suggesting existing data are sufficient for filing, despite failure of one of two pivotal trials.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.